Screening olfaction under dupilumab in chronic rhinosinusitis with nasal polyps.

Mauthe, T; Meerwein, C M; Ryser, F S; Brühlmann, C; Yalamanoglu, A; Steiner, U C; Soyka, M B (2024). Screening olfaction under dupilumab in chronic rhinosinusitis with nasal polyps. (In Press). Rhinology International Rhinologic Society 10.4193/Rhin23.476

Full text not available from this repository. (Request a copy)

BACKGROUND

Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently leads to olfactory dysfunction. This study aimed to assess the impact of dupilumab on CRSwNP patients, focusing on olfactory outcomes and potential correlations with other clinical factors.

METHODS

CRSwNP patients eligible for dupilumab therapy received subcutaneous Dupixent® injections every two weeks (300mg/2ml dupilumab). The 12-item Sniffin' Sticks Test (SST-12), fractional exhaled nitric oxide (FeNO) and Nasal Polyp Score (NPS) were assessed at baseline and after one, three, and six months. Patients also completed the Sino-Nasal Outcome Test (SNOT-22) weekly.

RESULTS

26 CRSwNP patients were included. After one month, dupilumab led to substantial reductions in FeNO, SNOT scores, andNPS, whereas SST-12 scores improved significantly only after three months. A shift toward normosmia occurred, with 81% achieving normosmia after six months, and a drop in anosmia prevalence to 9.5%. Significant negative correlations between olfaction (SST-12) and polyp severity (NPS) at baseline and after six months were found, while no significant correlations were observed between SST-12 and FeNO or SNOT scores. Age did not correlate with olfaction.

CONCLUSIONS

Dupilumab demonstrated efficacy in restoring olfaction in CRSwNP patients. Reaching normosmia in over 80% ofpatients after six months of treatment underscores the drug's effectiveness in managing this challenging symptom.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology

Graduate School:

Graduate School for Health Sciences (GHS)

UniBE Contributor:

Ryser, Fabio Simon, Steiner, Urs Christian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0300-0729

Publisher:

International Rhinologic Society

Language:

English

Submitter:

Pubmed Import

Date Deposited:

02 Jul 2024 09:38

Last Modified:

02 Jul 2024 09:38

Publisher DOI:

10.4193/Rhin23.476

PubMed ID:

38949841

URI:

https://boris.unibe.ch/id/eprint/198349

Actions (login required)

Edit item Edit item
Provide Feedback